US supplement regulation faces 30 years of unresolved debates and digital shifts

The regulation of dietary supplements in the US remains a complex and evolving issue. Nearly 30 years after the Dietary Supplement Health and Education Act (DSHEA) was passed, debates continue over enforcement, new ingredients, and industry transparency. Meanwhile, consumer awareness and marketing strategies have shifted dramatically in the digital age. DSHEA was introduced in 1994 as a compromise between lawmakers, regulators, and the supplement industry. The law defined dietary supplements as a category under the federal Food, Drug, and Cosmetic Act. It also created two groups of dietary ingredients—'old' and 'new'—while giving the FDA oversight over their safety and labelling.

Today, the FDA’s Office of Dietary Supplement Programs focuses on inspecting contract manufacturers to improve compliance. However, there is still no clear agreement on how to handle repeat offenders in the industry. Some argue for stricter enforcement, while others question whether current regulations are applied effectively.

One major unresolved issue is cannabidiol (CBD). The FDA maintains that no legal pathway exists for CBD products under current rules. Officials have called for a new regulatory structure, but progress has stalled. Meanwhile, the industry itself is divided on proposals like mandatory product listing (MPL), which would require companies to register their products with the FDA.

Outside regulation, the market has changed. Social media influencers and self-care campaigns now heavily shape consumer choices. At the same time, shoppers are far more informed about supplements than they were in the 1990s. Some industry observers remain hopeful that Congress could update DSHEA, particularly by expanding claims for functional foods. Yet, the political climate makes major legislative compromise unlikely. The future of supplement regulation depends on balancing stricter oversight with industry growth. While the FDA pushes for new frameworks, especially for CBD, lawmakers face challenges in reaching consensus. For now, enforcement remains inconsistent, and companies continue adapting to an increasingly informed—and digitally influenced—consumer base.